ArticleVirology journal2026
RRM2B is associated with low-level viremia during entecavir therapy in pediatric chronic hepatitis B and promotes profibrotic signaling in vitro.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLow-level viremia (LLV) during nucleos(t)ide analogue therapy for chronic hepatitis B (CHB) is clinically relevant, but its biological basis in children remains unclear. We investigated the clinical features of pediatric LLV and sought host factors linking incomplete virological suppression to stress adaptation and profibrotic signaling.
methodsChildren with CHB who initiated entecavir therapy between 2019 and 2024 were retrospectively enrolled. LLV and maintained virological response (MVR) were defined by serum HBV DNA at week 48. Longitudinal trajectories were analyzed using generalized estimating equation models. Public liver transcriptomic datasets were integrated to identify CHB-associated host candidates, which were prioritized by machine learning and validated in pediatric samples. Functional studies were performed in an entecavir-based LLV-like HepG2.2.15 model.
resultsAmong 109 children with CHB, 27.5% developed LLV. Compared with the MVR group, LLV was associated with higher baseline HBV pregenomic RNA (HBV pgRNA) and smaller declines in HBV DNA, aminotransferases, and APRI, with the earliest divergence at week 12. Integrated transcriptomic and machine-learning analyses identified 5,080 differentially expressed genes enriched in oxidative stress- and DNA damage-related pathways and prioritized RRM2B as a candidate host factor. RRM2B was elevated in pediatric LLV samples and correlated positively with HBV pgRNA. In vitro, low-dose entecavir induced an LLV-like state characterized by increased RRM2B, reactive oxygen species, γ-H2AX, and PI3K/AKT signaling. RRM2B silencing further suppressed HBV DNA replication, reduced oxidative stress and DNA damage, and attenuated LLV-like hepatocyte-derived TGF-β1 secretion and subsequent profibrotic activation of LX-2 cells.
conclusionsRRM2B is associated with pediatric LLV and may be involved in stress-related and profibrotic host responses under conditions of incomplete virological suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.